The report "Humanized Mouse and Rat Model Market by Type (Genetic Models, Cell-based Models, Rat Models), Application (Oncology, Immunology, Neuroscience, Toxicology, Infectious Diseases), End User (Pharma, Biotech), and Region - Global Forecast to 2030", is anticipated to reach USD 409.8 million in 2030 from USD 276.2 million in 2025, at a CAGR of 8.2%.
Browse 189 market data Tables and 31 Figures spread through 204 Pages and in-depth TOC on "Humanized Mouse and Rat Model Market by Type (Genetic Models, Cell-based Models, Rat Models), Application (Oncology, Immunology, Neuroscience, Toxicology, Infectious Diseases), End User (Pharma, Biotech), and Region - Global Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/humanized-mouse-model-market-131763955.html
Rising demand for personalized medicine is a crucial factor driving the humanized mouse and rat model market. The need for advanced innovative models grows as existing mouse models have certain limitations in predictive research, unable to effectively gauge response in human cancer patients. Advancements in proteomics, genomics, and metabolomics further boost the demand for personalized medicine. Additionally, demand for targeted diagnostics and preventive medicine is expected to propel the demand for humanized mouse and rat models.
The genetic models segment accounted for the largest share in humanized mouse and rat model type segment in 2024
Based on type, the humanized mouse and rat model market has been segmented into humanized mouse models and humanized rat models. The humanized mouse models segment is further divided into genetic humanized mouse models and cell-based humanized mouse models. The genetic models generated the highest revenue in 2024, and this segment is expected to continue this dominance throughout the forecast period. Genetic humanized mouse models have been successfully adopted in analyzing biological efficacy, safety testing, pharmaceutical compounds, and studying novel therapeutics. Humanized mouse models are gaining demand in studies around drug metabolism and immune system development & functioning.
The contract research organizations and contract development and manufacturing organization was the fastest-growing end user in 2024.
Based on end user, the humanized mouse and rat model market is segmented into pharmaceutical & biotechnology companies, CROs & CDMOs, and academic & research institutes. These organizations procure, maintain, and use humanized mice and rat models to deliver outsourced preclinical research services, particularly in immuno-oncology, cell and gene therapy, and biologics development. CROs serving as direct customers or technical end users of these models are included in this segment. These CROs purchase models from specialized vendors, such as Taconic Biosciences, Inc. (US), The Jackson Laboratory (US), and Hera BioLabs (US), to offer preclinical and clinical research services and generate efficacy, pharmacokinetic (PK/PD), and toxicology data.
Asia Pacific region is anticipated to grow at a significant CAGR during 2025–2030
The humanized mouse and rat model market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific market is estimated to register the highest growth during the forecast period. The increase in demand for market products across China and India contributes to this growth. Led by growing R&D activities, the outsourcing of preclinical, clinical, and laboratory testing services for small & large molecules is expected to increase in the country. The expanding pharmaceutical industry, the increasing number of CROs, and the rise in research activities will drive the growth of China’s humanized mouse and rat model market.
The report profiles key players such as Charles River Laboratories (US), The Jackson Laboratory (JAX) (US), Taconic Biosciences, Inc. (US), JSR Corporation (US) (Crown Biosciences), Champions Oncology, Inc. (US), CLEA Japan Inc. (Japan), genOway (France), Inotiv (US), Janvier Labs (France), Altogen Labs (US), Vitalstar Biotechnology (China), Ingenious Targeting Laboratory (US), Reaction Biology (US), Harbour BioMed (Netherlands), Oncodesign Services (France), Pharmatest Services (Finland), Ozgene Pty Ltd. (Australia), TransCure bioServices (France), Cyagen Biosciences (US), Aragen Life Sciences Ltd. (India), GemPharmatech (China), and Biocytogen (US), among others.
Comments (0)